Abstract
Monoamine oxidase B and Adenosine A2A receptors are used as key targets for Parkinson’s disease. Recently, hMAO-B and hA2AR Dual-targets inhibitory potential of a novel series of Phenylxanthine derivatives has been established in experimental findings. Hence, the current study examines the interactions between 38 compounds of this series with hMAO-B and hA2AR targets using different molecular modeling techniques to investigate the binding mode and stability of the formed complexes. A molecular docking study revealed that the compounds L24 ((E)-3-(3-Chlorophenyl)-N-(4-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl) phenyl) acrylamide and L32 ((E)-3-(3-Chlorophenyl)-N-(3-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)phenyl)acrylamide) had a high affinity (S-score: −10.160 and −7.344 kcal/mol) with the pocket of hMAO-B and hA2AR targets respectively, and the stability of the studied complexes was confirmed during MD simulations. Also, the MEP maps of compounds 24 and 32 were used to identify the nucleophilic and electrophilic attack regions. Moreover, the bioisosteric replacement approach was successfully applied to design two new analogs of each compound with similar biological activities and low energy scores. Furthermore, ADME-T and Drug-likeness results revealed the promising pharmacokinetic properties and oral bioavailability of these compounds. Thus, compounds L24, L32, and their analogs can undergo further analysis and optimization in order to design new lead compounds with higher efficacy toward Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data related to this study are included herein otherwise available on request.
References
Abdullah R, Basak I, Patil KS, Alves G, Larsen JP, Møller SG (2015) Parkinson’s disease and age: the obvious but largely unexplored link. Exp Gerontol 68:33–38. https://doi.org/10.1016/j.exger.2014.09.014
Anighoro A, Bajorath J, Rastelli G (2014) Polypharmacology: challenges and opportunities in drug discovery. J Med Chem 57:7874–7887
Azam F, Abodabos HS, Taban IM, Rfieda AR, Mahmood D, Anwar MJ, Khan S, Sizochenko N, Poli G, Tuccinardi T, Ali HI (2019) Rutin as promising drug for the treatment of Parkinson’s disease: an assessment of MAO-B inhibitory potential by docking, molecular dynamics and DFT studies. Mol Simul 45(18):1563–1571. https://doi.org/10.1080/08927022.2019.1662003
Bajda M, Więckowska A, Hebda M, Guzior N, Sotriffer CA, Malawska B (2013) Structure-based search for new inhibitors of cholinesterases. Int J Mol Sci 14(3):5608–5632. https://doi.org/10.3390/ijms14035608
Banerjee P, Eckert AO, Schrey AK (2018a) ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 46(W1):W257–W263. https://doi.org/10.1093/nar/gky318
Banerjee P, Dehnbostel FO, Preissner R (2018b) Prediction is a balancing act: importance of sampling methods to balance sensitivity and specificity of predictive models based on imbalanced chemical data sets. Front Chem. https://doi.org/10.3389/fchem.2018.00362
Bartolotti LJ, Flurchick K (1996) An introduction to density functional theory. In: Lipkowitz KB, Boyd D (eds) Reviews in computational chemistry, vol 7. VCH, New York, pp 187–260
Belaidi AA, Bush AI (2016) Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics. J Neurochem 139:179–197. https://doi.org/10.1111/jnc.13425
Belkadi A, Kenouche S, Melkemi N, Daoud I, Djebaili R (2021) K-means clustering analysis, ADME/pharmacokinetic prediction, MEP, and molecular docking studies of potential cytotoxic agents. Struct Chem 32(6):2235–2249. https://doi.org/10.1007/s11224-021-01796-w
Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A (2002) Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 9(1):22–26. https://doi.org/10.1038/nsb732
Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A (2007) Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 50(23):5848–5852. https://doi.org/10.1021/jm070677y
Bonaventura J, Rico AJ, Moreno E et al (2014) L-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus. Neuropharmacology 79:90–100. https://doi.org/10.1016/j.neuropharm.2013.10.036
Brünger A, Brooks IIICL, Karplus M (1984) Stochastic boundary conditions for molecular dynamics simulations of ST2 water. Chem Phys Lett 105(5):495–500. https://doi.org/10.1016/0009-2614(84)80098-6
Brunschweiger A, Koch P, Schlenk M, Pineda F, Küppers P, Hinz S, Müller CE (2014) 8-Benzyltetrahydropyrazino [2, 1-f] purinediones: water-soluble tricyclic xanthine derivatives as multitarget drugs for neurodegenerative diseases. Chem Med Chem 9(8):1704–1724. https://doi.org/10.1002/cmdc.201402082
Burley SK, Petsko GA (1985) Aromatic–aromatic interaction: a mechanism of protein structure stabilization. Science 229(4708):23–28. https://doi.org/10.1126/science.3892686
Carradori S, Petzer JP (2014) Novel monoamine oxidase inhibitors: a patent review (2012–2014). Expert Opin Ther Pat 25:91–101. https://doi.org/10.1517/13543776.2014.982535
Cavalli A, Bolognesi ML, Mìnarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347–372. https://doi.org/10.1021/jm7009364
Chaurasiya ND, Zhao J, Pandey P, Doerksen RJ, Muhammad I, Tekwani BL (2019) Selective inhibition of human monoamine oxidase B by acacetin 7-methyl ether isolated from turnera diffusa (Damiana). Molecules 24(4):810. https://doi.org/10.3390/molecules24040810
Chen JF, Cunha RA (2020) The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson’s disease. Purinergic Signal 16(2):167–174. https://doi.org/10.1007/s11302-020-09694-2
Chenafa H, Mesli F, Daoud I, Achiri R, Ghalem S, Neghra A (2021) In silico design of enzyme α-amylase and α-glucosidase inhibitors using molecular docking, molecular dynamic, conceptual DFT investigation and pharmacophore modelling. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2021.1882340
Cummins L, Cates ME (2022) Istradefylline: a novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease. Mental Health Clin 12(1):32–36. https://doi.org/10.9740/mhc.2022.01.032
Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7(1):1–13. https://doi.org/10.1038/srep42717
Daoud I, Melkemi N, Salah T, Ghalem S (2018) Combined QSAR, molecular docking and molecular dynamics study on new acetylcholinesterase and butyrylcholinesterase inhibitors. Comput Biol Chem 74:304–326. https://doi.org/10.1016/j.compbiolchem.2018.03.021
Dasgupta S, Mukherjee S, Sekar K, Mukhopadhyay BP (2021) The conformational dynamics of wing gates Ile199 and Phe103 on the binding of dopamine and benzylamine substrates in human monoamine Oxidase B. J Biomol Struct Dyn 39(5):1879–1886. https://doi.org/10.1080/07391102.2020.1734483
De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A (2005) Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci USA 102(36):12684–12689. https://doi.org/10.1073/pnas.0505975102
Doré AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, Hurrell E, Bennett K, Congreve M, Magnani F, Tate CG, Weir M, Marshall FH (2011) Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19(9):1283–1293. https://doi.org/10.1016/j.str.2011.06.014
Drwal MN, Banerjee P, Dunkel M, Wettig MR, Preissner R (2014) ProTox: a web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Res 42(W1):W53–W58. https://doi.org/10.1093/nar/gku401
Dungo R, Deeks ED (2013) Istradefylline: first global approval. Drugs 73(8):875–882. https://doi.org/10.1007/s40265-013-0066-7
Dunkel P, Chai CL, Sperlagh B, Huleat PB, Matyus P (2012) Clinical utility of neuroprotective agents in neurodegenerative disease: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis. Exp Opin Investig Drugs 21:1267–1308. https://doi.org/10.1517/13543784.2012.703178
Finberg JPM (2014) Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther 143(2):133–152. https://doi.org/10.1016/j.pharmthera.2014.02.010
Freitas ME, Fox SH (2016) Nondopaminergic treatments for Parkinson’s disease: current and future prospects. Neurodegener Dis Manage 6(3):249–268. https://doi.org/10.2217/nmt-2016-0005
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson G, Nakatsuji H (2009) Gaussian 09, Revision d. 01. Gaussian. Inc., Wallingford, CT
Hevener KE, Zhao W, Ball DM, Babaoglu K, Qi J, White SW, Lee RE (2009) Validation of molecular docking programs for virtual screening against dihydropteroate synthase. J Chem Inf Model 49(2):444–460. https://doi.org/10.1021/ci800293n
Hong R, Li X (2019) Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches. Med Chem Comm 10(1):10–25. https://doi.org/10.1039/C8MD00446C
Hu SW, Nian SY, Qin KY, Xiao T, Li L, Qi X, Ye F, Liang G, Hu G, He J, Yu Y, Song B (2012) Design, synthesis and inhibitory activities of 8-(substituted styrol-formamido) phenyl-xanthine derivatives on monoamine oxidase B. Chem Pharm Bull 60:385–390. https://doi.org/10.1248/cpb.60.385
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(1):33–38. https://doi.org/10.1016/0263-7855(96)00018-5
Ibrahim FAB, Rashid F, Hussain AAB, Alawadi F, Bashier A (2017) Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report. J Med Case Reports 11(1):1–4. https://doi.org/10.1186/s13256-017-1202-x
Imberty A, Hardman KD, Carver JP, Perez S (1991) Molecular modelling of protein-carbohydrate interactions. Docking of monosaccharides in the binding site of concanavalin A. Glycobiology 1(6):631–642. https://doi.org/10.1093/glycob/1.6.631
Jaiteh M, Zeifman A, Saarinen M, Svenningsson P, Bréa J, Loza MI, Carlsson J (2018) Docking screens for dual inhibitors of disparate drug targets for Parkinson’s disease. J Med Chem 61(12):5269–5278. https://doi.org/10.1021/acs.jmedchem.8b00204
Janiak C (2000) A critical account on n–n stacking in metal complexes with aromatic nitrogen-containing ligands. J Chem Soc Dalton Trans 21:3885–3896. https://doi.org/10.1039/b003010o
Jankovic J, Poewe W (2012) Therapies in Parkinson’s disease. Curr Opin Neurol 25:433–447. https://doi.org/10.1097/WCO.0b013e3283542fc2
Jeffrey GA, Jeffrey GA (1997) An introduction to hydrogen bonding, vol 12. Oxford University Press, New York, p 228
Kakkar AK, Dahiya N (2015) Management of Parkinson’s disease: current and future pharmacotherapy. EurJ Pharmacol 750:74–81. https://doi.org/10.1016/j.ejphar.2015.01.030
Koch P, Akkari R, Brunschweiger A, Borrmann T, Schlenk M, Küppers P, Müller CE (2013) 1, 3-Dialkyl-substituted tetrahydropyrimido [1, 2-f] purine-2, 4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. Bioorg Med Chem 21(23):7435–7452. https://doi.org/10.1016/j.bmc.2013.09.044
Kovacs JA, Chacón P, Abagyan R (2004) Predictions of protein flexibility: first-order measures. Proteins Struct Funct Bioinform 56(4):661–668. https://doi.org/10.1002/prot.20151
Lee C, Yang W, Parr RG (1988) Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B 37(2):785–789. https://doi.org/10.1103/PhysRevB.37.785
López-Blanco JR, Garzón JI, Chacón P (2011) iMod: multipurpose normal mode analysis in internal coordinates. Bioinformatics 27(20):2843–2850. https://doi.org/10.1093/bioinformatics/btr497
López-Blanco JR, Aliaga JI, Quintana-Ortí ES, Chacón P (2014) iMODS: internal coordinates normal mode analysis server. Nucleic Acids Res 42:W271–W276. https://doi.org/10.1093/nar/gku339
Lu T, Chen F (2012) Multiwfn: a multifunctional wavefunction analyzer. J Comput Chem 33(5):580–592. https://doi.org/10.1002/jcc.22885
McCormack PL (2014) Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. CNS Drugs 28(11):1083–1097. https://doi.org/10.1007/s40263-014-0206-y
Mellado M, Salas CO, Uriarte E, Viña D, Jara-Gutiérrez C, Matos MJ, Cuellar M (2019) Design, synthesis and docking calculations of prenylated chalcones as selective monoamine oxidase B inhibitors with antioxidant activity. Chemistry Select 4(26):7698–7703. https://doi.org/10.1002/slct.201901282
Meredith GE, Totterdell S, Beales B, Meshul CK (2009) Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson’s disease. Exp Neurol 219(1):334–340. https://doi.org/10.1016/j.expneurol.2009.06.005
Mesli F, Daoud I, Ghalem S (2019) Antidiabetic activity of Nigella sativa (BLACK SEED)-by molecular modeling elucidation, molecular dynamic, and conceptual DFT investigation. Pharmacophore 10(5):57–66
Molecular Operating Environment (MOE) (2014) 2014.09. Chemical Computing Group Inc.: 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7
Murray JS, Politzer P (2011) The electrostatic potential: an overview. Wiley Interdiscipl Rev Comput Mol Sci 1(2):153–163. https://doi.org/10.1002/wcms.19
Murray JS, Brinck T, Lane P, Paulsen K, Politzer P (1994) Statistically-based interaction indices derived from molecular surface electrostatic potentials: a general interaction properties function (GIPF). J Mol Struct (Theochem) 307:55–64. https://doi.org/10.1016/0166-1280(94)80117-7
Murray JS, Concha MC, Politzer P (2009) Links between surface electrostatic potentials of energetic molecules, impact sensitivities and C-NO2/N–NO2 bond dissociation energies. Mol Phys 107(1):89–97. https://doi.org/10.1080/00268970902744375
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361(13):1268–1278. https://doi.org/10.1056/NEJMoa0809335
Petzer JP, Castagnoli N, Schwarzschild MA, Chen JF, Van der Schyf CJ (2009) Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease. Neurotherapeutics 6:141–151. https://doi.org/10.1016/j.nurt.2008.10.035
Piovesan D, Minervini G, Tosatto SCE (2016) The RING 2.0 web server for high quality residue interaction networks. Nucleic Acids Res 44(W1):W367–W374. https://doi.org/10.1093/nar/gkw315
Pires DE, Blundell TL, Ascher DB (2015) pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
Pisani L, Catto M, Leonetti F, Nicolotti O, Stefanachi A, Campagna F, Carotti A (2011) Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases. Curr Med Chem 18(30):4568–4587
Raghavachari K (2000) Perspective on “Density functional thermochemistry. III. The role of exact exchange.” Theor Chem Acc 103:361–363. https://doi.org/10.1007/s002149900065
Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033–2043. https://doi.org/10.2174/0929867043364775
Rivara S, Piersanti G, Bartoccini F, Diamantini G, Pala D, Riccioni T, Stasi MA, Cabri W, Borsini F, Mor M, Tarzia G, Minetti P (2013) Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A2A antagonists/MAO-B inhibitors. J Med Chem 56(3):1247–1261. https://doi.org/10.1021/jm301686s
Sako W, Murakami N, Motohama K, Izumi Y, Kaji R (2017) The effect of istradefylline for Parkinson’s disease: a meta-analysis. Sci Rep 7:18018. https://doi.org/10.1038/s41598-017-18339-1
Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci 29(11):647–654. https://doi.org/10.1016/j.tins.2006.09.004
Shan J, Ji C (2020) MolOpt: a web server for drug design using bioisosteric transformation. Curr Comput Aided Drug Des 16(4):460–466. https://doi.org/10.2174/1573409915666190704093400
Simeonova R, Zheleva D, Valkova I, Stavrakov G, Philipova I, Atanasova M, Doytchinova I (2021) A novel galantamine-curcumin hybrid as a potential multi-target agent against neurodegenerative disorders. Molecules 26(7):1865. https://doi.org/10.3390/molecules26071865
Song B, Xiao T, Qi X, Li LN, Qin K, Nian S, Hu GX, Yu Y, Liang G, Ye F (2012) Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors. Bioorg Med Chem Lett 22:1739–1742. https://doi.org/10.1016/j.bmcl.2011.12.094
Stephenson J, Nutma E, van der Valk P, Amor S (2018) Inflammation in CNS neurodegenerative diseases. Immunology 154(2):204–219. https://doi.org/10.1111/imm.12922
Stitou M, Toufik H, Bouachrine M, Lamchouri F (2021) Quantitative structure–activity relationships analysis, homology modeling, docking and molecular dynamics studies of triterpenoid saponins as Kirsten rat sarcoma inhibitors. J Biomol Struct Dyn 39(1):152–170. https://doi.org/10.1080/07391102.2019.1707122
Stosel A, Schlenk M, Hinz S, Küppers P, Heer J, Gütschow M, Müller CE (2013) Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4H–3,1-benzothiazin-4-ones. J Med Chem 56(11):4580–4596. https://doi.org/10.1021/jm400336x
Sun C, Armstrong MJ (2021) Treatment of Parkinson’s disease with cognitive impairment: current approaches and future directions. Behav Sci 11(4):54. https://doi.org/10.3390/bs11040054
Szabo M, Lim HD, Klein Herenbrink C, Christopoulos A, Lane JR, Capuano B (2015) Proof of concept study for designed multiple ligands targeting the dopamine D2, serotonin 5-HT2A, and muscarinic M1 acetylcholine receptors. J Med Chem 58:1550–1555. https://doi.org/10.1021/jm5013243
Talati R, Reinhart K, Baker W, White CM, Coleman CI (2009) Pharmacologic treatment of advanced Parkinson’s disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Park Relat Disord 15(7):500–505. https://doi.org/10.1016/j.parkreldis.2008.12.007
Toda M, Kubo R, Saitō N, Hashitsume N (1991) Statistical physics II: nonequilibrium statistical mechanics, vol 2. Springer Science & Business Media, New York
Tóth A, Antal Z, Bereczki D, Sperlágh B (2019) Purinergic signalling in Parkinson’s disease: a multi-target system to combat neurodegeneration. Neurochem Res 44(10):2413–2422. https://doi.org/10.1007/s11064-019-02798-1
Toumi A, Boudriga S, Hamden K, Daoud I, Askri M, Soldera A, Jean-Francois L, Carsten S, Lukas B, Knorr M (2021) Diversity-oriented synthesis of spiropyrrolo [1, 2-a] isoquinoline derivatives via diastereoselective and regiodivergent three-component 1,3-dipolar cycloaddition reactions: in vitro and in vivo evaluation of the antidiabetic activity of rhodanine analogues. J Org Chem 86(19):13420–13445. https://doi.org/10.1021/acs.joc.1c01544
Tzvetkov NT, Antonov L (2017) Subnanomolar indazole-5-carboxamide inhibitors of monoamine oxidase B (MAO-B) continued: indications of iron binding, experimental evidence for optimised solubility and brain penetration. J Enzyme Inhib Med Chem 32(1):960–967. https://doi.org/10.1080/14756366.2017.1344980
Van der Walt MM, Terre’Blanche G, Petzer A, Petzer JP (2015) The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues. Bioorg Chem 59:117–123. https://doi.org/10.1016/j.bioorg.2015.02.005
Wade RC, Goodford PJ (1989) The role of hydrogen-bonds in drug binding. Prog Clin Biol Res 289:433–444
Wang W, Skeel RD (2003) Analysis of a few numerical integration methods for the Langevin equation. Mol Phys 101(14):2149–2156. https://doi.org/10.1080/0026897031000135825
Wang X, Han C, Xu Y, Wu K, Chen S, Hu M, Wang L, Ye Y, Ye F (2017) Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson’s disease. Molecules 22(6):1010. https://doi.org/10.3390/molecules22061010
Wenzel TJ, Klegeris A (2018) Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer’s disease. Life Sci 207:314–322. https://doi.org/10.1016/j.lfs.2018.06.025
Wu WY, Dai YC, Li NG, Dong ZX, Gu T, Shi ZH, Duan JA (2017) Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer’s disease. J Enzyme Inhib Med Chem 32(1):572–587. https://doi.org/10.1080/14756366.2016.1210139
Yang T, Sui X, Yu B, Shen Y, Cong H (2020) Recent advances in the rational drug design based on multi-target ligands. Curr Med Chem 27(28):4720–4740. https://doi.org/10.2174/0929867327666200102120652
Youdi MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309. https://doi.org/10.1038/nrn1883
Załuski M, Schabikowski J, Schlenk M, Olejarz-Maciej A, Kubas B, Karcz T, Kieć-Kononowicz K (2019) Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies. Bioorg Med Chem 27(7):1195–1210. https://doi.org/10.1016/j.bmc.2019.02.004
Zhukov A, Andrews SP, Errey JC, Robertson N, Tehan B, Mason JS, Marshall FH, Weir M, Congreve M (2011) Biophysical mapping of the adenosine A2A receptor. J Med Chem 54(13):4312–4323. https://doi.org/10.1021/jm2003798
Acknowledgements
Authors thanks the Algerian Ministry of Higher Education and Scientific Research for the support under the PRFU project (approval No. B00L01UN130120190009) and ensure that there is no conflict of interest regarding this paper.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mettai, M., Daoud, I., Mesli, F. et al. Molecular docking/dynamics simulations, MEP analysis, bioisosteric replacement and ADME/T prediction for identification of dual targets inhibitors of Parkinson’s disease with novel scaffold. In Silico Pharmacol. 11, 3 (2023). https://doi.org/10.1007/s40203-023-00139-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40203-023-00139-3